| ￥3300 | |
| Z05197-100 | |
|
|
|
|
|
|
|
|
|
| Species | Human | ||||
| Protein Construction |
|
||||
| Purity |
> 95% as determined by BisTris PAGE > 90% as determined by HPLC |
||||
| Endotoxin Level | Less than 1EU per μg by the LAL method. | ||||
| Expression System | HEK293 | ||||
| Theoretical Molecular Weight | 42.47 kDa | ||||
| Apparent Molecular Weight | Due to glycosylation, the protein migrates to 52-62 kDa based on Bis-Tris PAGE result. | ||||
| Formulation | Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). | ||||
| Reconstitution | Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. | ||||
| Storage & Stability | Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
The purity of CSPG5, His, Human is greater than 90% as determined by SEC-HPLC. »
CSPG5, His, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%. »
| Target Background | Chondroitin sulfate proteoglycan 5 (CSPG-5), also known as neuroglycan C, has been previously associated to differentiation since it shapes neurite growth and synapse forming. CSPG-5 expression shifts in brain areas of the default mode network of suicide victims, which may reflect an impact in the pathogenesis of psychiatric diseases or support diagnostic power. |
| Synonyms | Neuroglycan C;CALEB;MGC44034;Neuroglycan C;NGC; |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
